Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 6, 2011, Pages 437-441

  Dasenbrook, Elliott C ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

borderline oxacillin resistant Staphylococcus aureus; cystic fibrosis; epidemiology; methicillin resistant Staphylococcus aureus; small colony variant

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PREVALENCE; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 80053349019     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32834b95ed     Document Type: Review

References (29)

1. Boyle MP. Adult cystic fibrosis. J Am Med Assoc 2007; 298:1787-1793. (Pubitemid 47598447)
2. Cystic Fibrosis Foundation Patient, 2009 Annual Data Report. Bethesda, MD. 2011.
3. Liou TG, Adler FR, FitzSimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153:345-352. (Pubitemid 32144560)
4. Sawicki GS, Rasouliyan L, Pasta DJ, et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008; 43:1117-1123.
5. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-59. (Pubitemid 36099097)
6. Elizur A, Orscheln RC, Ferkol TW, et al. Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007; 131:1718-1725. (Pubitemid 46981625)
7. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46 (Suppl 5):S350-S359. (Pubitemid 351717322)
8. Dasenbrook EC, Merlo CA, Diener-West M, et al. Persistent methicillinresistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:814-821.
9. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182:627-632.
10. Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. J Am Med Assoc 2010; 303:2386-2392.
11. Leahy TR, Yau YC, Atenafu E, et al. Epidemiology of borderline oxacillinresistant Staphylococcus aureus in pediatric cystic fibrosis. Pediatr Pulmonol 2011 [Epub ahead of print].
12. Vu-Thien H, Hormigos K, Corbineau G, et al. Longitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variablenumber of tandem-repeats analysis method. BMC Microbiol 2010; 10:24.
13. Melter O, Radojevic B. Small colony variants of Staphylococcus aureus: review. Folia Microbiol (Praha) 2010; 55:548-558.
14. Green N, Burns JL, Mayer-Hamblett N et al. Lack of association of smallcolony-variant staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. J Clin Microbiol 2011; 49:2772-2773.
15. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. J Am Med Assoc 2010; 303:1707-1715.
16. Mitchell G, Gattuso M, Grondin G, et al. Tomatidine inhibits replication of Staphylococcus aureus small-colony variants in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2011; 55:1937-1945.
17. Saiman L. Infection prevention and control in cystic fibrosis. Curr Opin Infect Dis 2011; 24:390-395.
18. Stone A, Quittell L, Zhou J, et al. Staphylococcus aureus nasal colonization among pediatric CF patients and their household contacts. Pediatr Infect Dis J 2009; 28:895-899.
19. Doe SJ, McSorley A, Isalska B, et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010; 9:104-109.
20. Hayes D Jr, Murphy BS, Mullett TW, Feola DJ. Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology 2010; 15:184-186.
21. Cafiso V, Bertuccio T, Spina D, et al. Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2010; 29:1277-1285.
22. Filleron A, Chiron R, Reverdy ME, et al. Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients. J Cyst Fibros 2011 [Epub ahead of print].
23. Endimiani A, Blackford M, Dasenbrook EC, et al. Emergence of linezolidresistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother 2011; 55:1684-1692
24. Hill RL, Kearns AM, Nash J, et al. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 2010; 65:442-445.
25. Keel RA, Schaeftlein A, Kloft C, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother 2011; 55:3393-3398.
26. Santos RP, Prestidge CB, Brown ME, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol 2009; 44:148-154.
27. McGhee P, Clark C, Credito K, et al. In vitro activity of fusidic acid CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia. Antimicrob Agents Chemother 2011; 55:2417-2419.
28. Craft JC, Moriarty SR, Clark K, et al. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 2011; 52 (Suppl 7):S520-S526.
29. Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother 2010; 65:1853-1861.